A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Clinical trial NCT07287982 · RECRUITING

Trial details

NCT number: NCT07287982
Sponsor: argenx
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Spinal Muscular Atrophy (SMA)

Start date: 2025-12-19
Primary completion: 2029-05-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.